Brachytherapy
Volume 5, Issue 1 , Pages 5-6 , January 2006

High-dose-rate versus low-dose-rate monotherapy in the treatment of localized prostate cancer: The case for low-dose-rate monotherapy

References 

  1. Grills IS, Martinez AA, Hollander M, et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol. 2004;171:1098–1104
  2. Yoshioka Y, Nose T, Yoshida K, et al. High dose rate brachytherapy as monotherapy for localized prostate cancer: A retrospective analysis with special focus on tolerance and chronic toxicity. Int J Radiat Oncol Biol Phys. 2003;56:213–220
  3. Grimm PD, Blasko JC, Sylvester JE, et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:31–40
  4. Kollmeier MA, Stock RG, Stone NN. Biochemical outcomes after prostate brachytherapy with 5 year minimal follow-up: Importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys. 2003;57:645–653
  5. Potters L, Klein EA, Kattan MW, et al. Monotherapy for stage T1–T2 prostate cancer: Radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol. 2004;71:29–33
  6. Al-Booz H, Ash D, Bottomley DM, et al. Short-term morbidity and acceptability of 125iodine implantation for localized carcinoma of the prostate. BJU Int. 1999;83:53–56
  7. Arterbery VE, Frazier A, Dalmia P, et al. Quality of life after permanent prostate implant. Semin Surg Oncol. 1997;13:461–464
  8. Merrick GS, Butler WM, Wallner KE, et al. Dysuria after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;55:979–985
  9. Stock RG, Kao J, Stone NN. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol. 2001;165:436–439
  10. Zelefsky MJ, Yamada Y, Marion C, et al. Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;55:956–963
  11. Stock RG, Stone NN, Dahlal M, et al. What is the optimal dose for 125I prostate implants? A dose–response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms. Brachytherapy. 2002;1:83–89
  12. Martinez AA, Pataki I, Edmundson G, et al. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: A feasibility report. Int J Radiat Oncol Biol Phys. 2001;49:61–69

PII: S1538-4721(06)00005-5

doi: 10.1016/j.brachy.2006.01.003

Brachytherapy
Volume 5, Issue 1 , Pages 5-6 , January 2006

Article Tools